A Systematic Review of National Drug Negotiations

Abstract

Purpose: The national drug negotiation work continues to deepen. Although the negotiation mechanism is becoming mature, there are still deficiencies. Through combing the current negotiation policy content, deficiencies are found, and suggestions for improvement are put forward on this basis. Method: Use the policy comparison method to sort out the contents of the five rounds of national drug negotiations, find out the points to be improved in the policy, and then use the literature search method to put forward suggestions for improvement. Result: The current national drug negotiation work is constantly improving, but there are still shortcomings, such as the issue of reciprocity in the negotiation and the lack of rare disease drugs in the catalog. Conclusion: Dynamic drug price adjustments, third-party regulatory agencies, and special protection for rare diseases have important reference significance for solving the current deficiencies in the country's drug negotiation work